SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > US Listed > Mining/Resources >

India Globalization Capital Inc (IGC)

IGC RSS Feed
Add IGC Price Alert      Hide Sticky   Hide Intro
Moderator: NetworkNewsWire
Search This Board: 
Last Post: 6/25/2017 5:24:02 AM - Followers: 93 - Board type: Free - Posts Today: 1

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first-mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio

IGC recently exited its legacy businesses and currently holds international investments in land and in a hotel project.

 

Investment Highlights

  • Building a patented portfolio of phytocannabinoid-based pharmaceutical and nutraceutical products for one of the world's fastest growing industries
    Positioning for first-mover advantage by developing novel therapies, applying for patents, and acquiring technologies from related industries
    Strategic alliance with International Pharma Trials provides expertise in the FDA process and pharma-trials

 


Development Pipeline

Through cutting-edge research, IGC is developing a product portfolio of phytocannabinoid-based therapies for the treatment of a wide range of life altering or life threatening indications, including neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis.


Target Markets

Attitudes toward cannabis have transformed substantially across the United States. Support for cannabis legalization is rapidly outpacing opposition; 53 percent of Americans believe cannabis should be made legal, compared with 44 percent supporting illegality of cannabis. Within this burgeoning market, IGC has identified key areas to which it can apply its phytocannabinoid-based therapies to address unmet medical needs.

 

Pain

The treatment of pain is a great challenge for health care professionals as it can often debilitate individuals in ways that affect their day-to-day functioning, which significantly impacts the nation's productivity and economy. The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion.

A major disadvantage of using currently available drug therapies to treat chronic severe pain is that these opioid based drugs may lead to side effects like hallucinations, constipation, sedation, nausea, respiratory depression, and dysphoria.

IGC-501

IGC has applied for a U.S patent based on a novel therapy, IGC-502 indicated for seizures, using cannabinoid extracts. The therapy is administered, using a variety of delivery technologies, for indications in mammals such as dogs and cats. The therapy may also be useful in humans.

IGC expects to conduct metabolic profiling and apply to the FDA for trials over the next few years.

 

Epilepsy

Approximately 50 million people worldwide are affected by epilepsy (Sanders, 2003), a condition attributed to multiple factors. In dogs and cats, seizures are often caused by abnormal brain activity. They can be subtle or cause violent convulsions. Some seizures only occur once, but repeated seizures require treatment to prevent larger areas of the brain from becoming affected.

IGC-502

IGC has applied for a U.S patent based on a novel therapy, IGC-502 indicated for seizures, using cannabinoid extracts. The therapy is administered, using a variety of delivery technologies, for indications in mammals such as dogs and cats. The therapy may also be useful in humans.

IGC expects to conduct metabolic profiling and apply to the FDA for trials over the next few years.

 

Eating Disorders

Cachexia is a condition that accompanies severe illness such as cancer and results in the weakness and wasting away of the body. Approximately 1.3 million people in the United States are experiencing cachexia associated with cancer, multiple sclerosis, Parkinson's disease, HIV/AIDS, and other progressive illnesses. Notably, cancer-induced anorexia/cachexia is responsible for about 20% of all cancer deaths.

IGC-504 and IGC-506

Indicated for a variety of eating disorders, including cachexia, IGC-504 and IGC 506 are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies. IGC-506 is being developed for both human and veterinary use.

 


Industry Partnerships

IGC has established a strategic alliance with International Pharma Trials, whose doctors and researchers have expertise in disorders of the central and peripheral nervous system as well as expertise in the FDA process and pharma-trials.

The company continues to seek information exchanges with medical cannabis dispensaries, research scientists, doctors, medical and business professionals, and biotech companies working in the cannabinoid space.

Leveraging its business model and collaborative research, IGC can help commercialize products while finding innovative ways of helping patients benefit from cannabinoids.

 


Leadership


Ram Mukunda, President, CEO and Director

Ram Mukunda has served as IGC's executive chairman, chief executive officer, and president since the company's inception on April 29, 2005. From January 1990 to May 2004, Mukunda served as founder, chairman, and chief executive officer of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec was the first pure play international long distance carrier. Mukunda was responsible for organizing, structuring and integrating a number of companies owned by Startec. Under Mukunda's tenure at Startec, the company made an IPO of its equity securities in 1997 on NASDAQ. Prior to Startec, Mr. Mukunda served as Strategic Planning Advisor at Intelsat, a communications satellite services provider.

Mukunda serves as an emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a council member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs.

Mukunda is the recipient of several awards including, the 2013 University of Maryland's International Alumnus of the Year award, the 2001 Distinguished Engineering Alumnus Award, the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S degree in Mathematics, and a M.S. in Engineering from the University of Maryland.

John Cherin, CFO, Treasurer, PAO

John Cherin is a retired senior executive with international experience in assisting young companies. He has provided insight to top management and Board of Directors on strategic analysis and improvement of operating procedures in financial reporting and operations. From 1966 to 1997, Cherin gained his experience as a senior partner at Arthur Andersen while managing practices aimed at businesses in the US and overseas. In addition he founded and managed Cherin Global Consulting in 1997-2005 and the Cherin Group LLC in 2004 to date. He also served as CFO for IGC in its formative stages for the purpose of raising capital to enable IGC's launch in the post startup phase.

Cherin is a retired CPA, a graduate of Northeastern University class of 1966 and in 1967 was the Silver Medal Recipient from the Massachusetts Society of CPAs.

Claudia Grimaldi, General Manager, Director of Cabaran Ultima

Claudia Grimaldi is the general manager and director of IGC's project development and managing company in Malaysia. Grimaldi is responsible for coordinating the staff in various countries and ensuring timely and accurate regulatory compliance and statutory reporting. Prior to assuming her current role in 2013, she spent three years managing the office of the CEO.

Prior to IGC, Grimaldi worked in human resources and psychotherapy. She graduated Summa Cum Laude from Javeriana University, a top five University in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College. Grimaldi is a member of Delta Mu Delta International Honor Society. She is also fluent in both English and Spanish.

 


India Globalization Capital
PO BOX 60642
Potomac, MD 20859-0642
Phone: (301) 983-0998
www.IGCinc.us

NetworkNewsWire
1324 Lexington Ave.
Suite 117
New York, NY 10128
Phone: (212) 418-1217
www.NetworkNewsWire.com

 

NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website: https://www.networknewswire.com/disclaimer/

IGC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IGC News: Pharmaceutical Leaders Pave the Way to New Alzheimer’s Treatments 06/15/2017 07:00:00 AM
IGC News: Current Report Filing (8-k) 06/12/2017 09:01:10 AM
IGC News: Pre-Market Technical Pulse on Steel & Iron Stocks -- Commercial Metals, Companhia Siderurgica Nacional, Reliance Steel & Alum... 06/05/2017 06:52:00 AM
IGC News: Current Report Filing (8-k) 05/25/2017 04:11:20 PM
IGC News: Cannabis-Based Therapies with Potential to Dull the Pain of Opioid Abuse 05/17/2017 08:45:00 AM
PostSubject
#5111   What a bullshit. Scherf.com the gambler. His arts kondziu 06/25/17 05:24:02 AM
#5110   I agree with your statement. Especially the last Smilin_B 06/19/17 04:09:52 PM
#5108   MUST BE PAYROLL WEEK FOR RAM THE SCAM! Sprycel 06/19/17 03:43:21 PM
#5107   Pharmaceutical Leaders Pave the Way to New Alzheimer’s Treatments NetworkNewsWire 06/15/17 07:00:15 AM
#5106   Dude, im engaging in conversation here. The bold Striker77 06/14/17 12:22:53 PM
#5105   EVERY SINGLE NEWS ANNOUNCEMENT IS LEAD WITH SELLING Sprycel 06/14/17 12:20:58 PM
#5104   In some cases, even if it was a Striker77 06/14/17 12:18:11 PM
#5103   LOL, he has been changing BS stories for Sprycel 06/14/17 12:13:50 PM
#5102   I understand that, but you have to figure Striker77 06/14/17 12:10:27 PM
#5101   Startup????????????? This ain't no startup! He Sprycel 06/14/17 12:04:16 PM
#5100   300k isnt much at all for an executive Striker77 06/14/17 12:00:39 PM
#5099   Remember the company has a $20 million share Sprycel 06/14/17 11:03:09 AM
#5098   Starting to get more trades going and bigger Striker77 06/13/17 06:04:15 PM
#5097   IGC Becomes Exclusive Licensee of Cannabis-Based Treatment for NetworkNewsWire 06/12/17 09:03:54 AM
#5096   IGC reach major milestone in regards to Alzheimers SBPartners 06/12/17 08:04:54 AM
#5095   *yawn* no ones interested Smilin_B 06/07/17 03:20:53 PM
#5094   IGC Pursues Clinical Trials of Cannabis-Based Combination Therapies NetworkNewsWire 06/07/17 10:20:18 AM
#5093   IGC Targets Human and Veterinary Epilepsy with Innovative NetworkNewsWire 06/06/17 03:07:36 PM
#5092   Slowly building back up. Trades were bigger and Striker77 06/03/17 12:33:45 AM
#5091   DOWN ANOTHER 2%!!! NICE JOB!!! Sprycel 05/24/17 04:51:10 PM
#5090   IGC Taps Dr. Craig Cheifetz as Advisor for NetworkNewsWire 05/24/17 03:12:23 PM
#5089   IGC Developing Phytocannabinoid-Based Product Pipeline to Treat Two- NetworkNewsWire 05/22/17 09:22:37 AM
#5088   It is kind of entertaining I guess....lol Striker77 05/19/17 09:12:50 PM
#5087   That's a lot of effort putting in to devilskyvin 05/19/17 05:45:10 PM
#5086   That makes at least 3 or 4 people surfer44 05/19/17 12:37:51 AM
#5085   Its like a never ending record. If someone Striker77 05/19/17 12:11:13 AM
#5084   U know this is penny land right? devilskyvin 05/18/17 11:13:14 PM
#5083   You can review the short report on this Sprycel 05/18/17 10:54:30 PM
#5082   To make sure RAM the SCAM does not Sprycel 05/18/17 10:53:12 PM
#5081   Ok now I get it you are a short devilskyvin 05/18/17 07:11:42 PM
#5080   Why are u here? devilskyvin 05/18/17 07:11:00 PM
#5079   NO REVENUE BUT THE CEO PAYS HIMSELF $300,000.00 Sprycel 05/18/17 03:20:09 PM
#5078   IGC is Blazing a Trail with its Cannabis NetworkNewsWire 05/18/17 11:51:40 AM
#5077   Cannabis-Based Therapies with Potential to Dull the Pain NetworkNewsWire 05/17/17 08:50:18 AM
#5076   And it's down another 8%!!!!! What is Sprycel 05/16/17 03:05:25 PM
#5075   IGC Adds Craig Cheifetz, M.D. to Advisory Team NetworkNewsWire 05/16/17 10:46:55 AM
#5074   Agree. Buy a basket of stocks. surfer44 05/10/17 12:02:25 AM
#5073   When Canada legalizes MJ any cannabis stock out Striker77 05/09/17 11:19:06 PM
#5072   lolol i couldn't agree with you more concerning Smilin_B 05/09/17 12:46:16 PM
#5070   No I actually walked away from this scam Sprycel 05/08/17 06:39:32 PM
#5068   STOCK IS DOWN 20% SINCE THE NEWS CAME Sprycel 05/08/17 02:46:47 PM
#5067   IGC Positioned to Lead in Phytocannabinoid Pharmaceuticals NetworkNewsWire 05/08/17 12:58:20 PM
#5066   IGC Engages a Critical Point in Cannabis History NetworkNewsWire 05/05/17 02:39:54 PM
#5065   IGC Strategically Staking Claims in the Medical Marijuana Markets NetworkNewsWire 05/04/17 12:30:12 PM
#5064   Paws Firmly Planted for Growth in Multibillion-Dollar Pet NetworkNewsWire 05/03/17 08:47:51 AM
#5063   GET READY FOR ANOTHER RAM THE SCAM SELL Sprycel 05/03/17 08:34:15 AM
#5062   It is RAM THE SCAM, 'FUND THE PAYROLL Sprycel 05/01/17 12:53:42 PM
#5061   Sorry, there is no riding anything up on Sprycel 04/27/17 07:55:19 PM
#5060   So ride it up and get out, more Striker77 04/27/17 05:45:05 PM
#5059   The pump promotion company is getting paid $3000.00 Sprycel 04/27/17 03:06:55 PM
PostSubject